Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

Merck and a woman suing the drugmaker agreed to halt a trial over alleged injuries from the drugmaker's human papillomavirus ...

Merck & Co.’s first trial over the safety of its blockbuster Gardasil cancer vaccine was cut short and rescheduled amid ...

Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new ...

Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...

Chinese consumers, once the engine of growth for multinational companies, are cutting back on all kinds of things. Designer ...

Lawsuits surrounding Merck's HPV vaccine Gardasil have been piling up for years now, but they've garnered increased public ...

Shares of Merck & Co. Inc. MRK rallied 2.08% to $89.50 Friday, on what proved to be an all-around rough trading session for ...

Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $112.46, a high ...

LOS ANGELES, CA / / February 23, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of ...

It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings report. Even as the pharmaceutical giant exceeded Wall Street estimates ...